-
EP3325016
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3325016
| EP3325016 - PHARMACEUTICAL COMPOSITION COMPRISING AN ADENOVIRAL VECTOR [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 17.11.2023 Database last updated on 06.07.2024 | |
| Former | Grant of patent is intended Status updated on 18.06.2023 | ||
| Former | Examination is in progress Status updated on 02.05.2023 | ||
| Former | Grant of patent is intended Status updated on 23.02.2023 | ||
| Former | Examination is in progress Status updated on 04.09.2019 | ||
| Former | Request for examination was made Status updated on 27.04.2018 | ||
| Former | The international publication has been made Status updated on 27.01.2017 | Most recent event Tooltip | 05.07.2024 | Lapse of the patent in a contracting state New state(s): IS | published on 07.08.2024 [2024/32] | Applicant(s) | For all designated states GlaxoSmithKline Biologicals SA Rue de l'Institut, 89 1330 Rixensart / BE | [2023/23] |
| Former [2018/22] | For all designated states GlaxoSmithKline Biologicals S.A. Rue de l'Institut, 89 1330 Rixensart / BE | Inventor(s) | 01 /
BOURLES, Erwan GlaxoSmithKline Biologicals SA Rue de l'Institut 89 B-1330 Rixensart / BE | 02 /
MATHOT, Frédéric GlaxoSmithKline Biologicals SA Rue de l'Institut 89 B-1330 Rixensart / BE | [2018/22] | Representative(s) | Jenkinson, Kay Elizabeth GlaxoSmithKline 980 Great West Road Brentford, Middlesex, TW8 9GS / GB | [2018/22] | Application number, filing date | 16751192.2 | 20.07.2016 | [2018/22] | WO2016EP67280 | Priority number, date | GB20150013010 | 23.07.2015 Original published format: GB 201513010 | [2018/22] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017013169 | Date: | 26.01.2017 | Language: | EN | [2017/04] | Type: | A1 Application with search report | No.: | EP3325016 | Date: | 30.05.2018 | Language: | EN | The application published by WIPO in one of the EPO official languages on 26.01.2017 takes the place of the publication of the European patent application. | [2018/22] | Type: | B1 Patent specification | No.: | EP3325016 | Date: | 20.12.2023 | Language: | EN | [2023/51] | Search report(s) | International search report - published on: | EP | 26.01.2017 | Classification | IPC: | A61K47/26, A61K39/235, A61K9/19 | [2018/22] | CPC: |
A61K9/19 (EP,US);
A61K39/12 (EP,US);
A61K47/02 (US);
A61K47/26 (EP,US);
A61P37/04 (EP);
A61P43/00 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/22]
| Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN ADENOVIRALEN VEKTOR | [2023/10] | English: | PHARMACEUTICAL COMPOSITION COMPRISING AN ADENOVIRAL VECTOR | [2018/22] | French: | COMPOSITION PHARMACEUTIQUE COMPRENANT UN VECTEUR ADRENOVIRAL | [2023/10] |
| Former [2018/22] | PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT EINEM ADENOVIRUSVEKTOR | ||
| Former [2018/22] | COMPOSITION PHARMACEUTIQUE COMPRENANT UN VECTEUR ADÉNOVIRAL | Entry into regional phase | 16.02.2018 | National basic fee paid | 16.02.2018 | Designation fee(s) paid | 16.02.2018 | Examination fee paid | Examination procedure | 16.02.2018 | Examination requested [2018/22] | 16.02.2018 | Date on which the examining division has become responsible | 11.09.2018 | Amendment by applicant (claims and/or description) | 09.09.2019 | Despatch of a communication from the examining division (Time limit: M06) | 24.02.2020 | Reply to a communication from the examining division | 17.11.2020 | Despatch of a communication from the examining division (Time limit: M04) | 10.03.2021 | Reply to a communication from the examining division | 24.02.2023 | Communication of intention to grant the patent | 02.05.2023 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 19.06.2023 | Communication of intention to grant the patent | 10.10.2023 | Fee for grant paid | 10.10.2023 | Fee for publishing/printing paid | 10.10.2023 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 10.07.2018 | Renewal fee patent year 03 | 09.07.2019 | Renewal fee patent year 04 | 10.07.2020 | Renewal fee patent year 05 | 20.07.2021 | Renewal fee patent year 06 | 21.07.2022 | Renewal fee patent year 07 | 20.07.2023 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HR | 20.12.2023 | RS | 20.12.2023 | NO | 20.03.2024 | GR | 21.03.2024 | IS | 20.04.2024 | [2024/32] |
| Former [2024/24] | HR | 20.12.2023 | |
| RS | 20.12.2023 | ||
| NO | 20.03.2024 | ||
| GR | 21.03.2024 | ||
| Former [2024/20] | GR | 21.03.2024 | Cited in | International search | [X]US2002182723 (ZHANG SHUYUAN [US], et al) [X] 39,41,43,61 * example 14 *; | [X]CN1883707 (UNIV JILIN [CN]) [X] 39,41,43,61* examples 1-3 *; | [XY]US2013164296 (DREW JEFFREY [GB], et al) [X] 1,2,4,5,7,11 * paragraph [0288] - paragraph [0372] * [Y] 1-38; | [XY]US2014073032 (CUSTERS JEROME H H V [NL], et al) [X] 1,2,4,5,7,11,12,14-30,33,37,38 * paragraph [0066] - paragraph [0067] * * paragraph [0003] - paragraph [0004] * * paragraph [0038] * [Y] 1-38; | [XY] - P.E. CRUZ ET AL, "Screening of Novel Excipients for Improving the Stability of Retroviral and Adenoviral Vectors", BIOTECHNOLOGY PROGRESS, (20060407), vol. 22, no. 2, doi:10.1021/bp050294y, ISSN 8756-7938, pages 568 - 576, XP055183405 [X] 1,2,4,5,7-9,20-25,27-29,33 * the whole document * [Y] 1-38 DOI: http://dx.doi.org/10.1021/bp050294y | [A] - PERUZZI D ET AL, "A novel Chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines", VACCINE, ELSEVIER LTD, GB, vol. 27, no. 9, doi:10.1016/J.VACCINE.2008.12.051, ISSN 0264-410X, (20090225), pages 1293 - 1300, (20090120), XP026194421 [A] 1-38 * the whole document * DOI: http://dx.doi.org/10.1016/j.vaccine.2008.12.051 |